0000899243-17-002741.txt : 20170203
0000899243-17-002741.hdr.sgml : 20170203
20170203171145
ACCESSION NUMBER: 0000899243-17-002741
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170201
FILED AS OF DATE: 20170203
DATE AS OF CHANGE: 20170203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pfeffer Cary
CENTRAL INDEX KEY: 0001591092
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 17573005
MAIL ADDRESS:
STREET 1: C/O ELEVEN BIOTHERAPEUTICS
STREET 2: 215 FIRST STREET, SUITE 400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-01
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001591092
Pfeffer Cary
C/O THIRD ROCK VENTURES, LLC,
29 NEWBURY STREET, 3RD FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2017-02-01
4
C
0
0
A
0
I
See Footnote
Common Stock
2017-02-01
4
C
0
0
A
0
I
See Footnote
Series A Preferred Stock
2017-02-01
4
C
0
0
0.00
D
Common Stock
0
0
I
See Footnote
Series A Preferred Stock
2017-02-01
4
C
0
0
0.00
D
Common Stock
0
0
I
See Footnote
Third Rock Ventures II, L.P. ("TRV II") received 9,688,344 shares of Common Stock upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
Third Rock Ventures III, L.P. ("TRV III") received 3,048,780 shares of Common Stock upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. TRV II and TRV III converted 35,750,000 and 11,250,000 shares of Series A Preferred Stock into Common Stock, respectively, upon the closing of the Issuer's initial public offering.
TRV II directly holds 10,230,349 shares of Common Stock. The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
TRV III directly holds 3,048,780 shares of Common Stock. The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of the TRV III. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
/s/ Cary Pfeffer
2017-02-03